Table 3.
GEE models for the impact of clinical factors on the changes in BCVA after treatment.
| All subjects | Responder group | Non-responder group | ||||
|---|---|---|---|---|---|---|
| B (S.E.) | P value | B (S.E.) | P value | B (S.E.) | P value | |
| Age (years) | −0.016 (0.005) | 0.001* | −0.002 (0.004) | 0.553 | −0.008 (0.005) | 0.070 |
| HbA1c (%) | −0.056 (0.033) | 0.086 | −0.060 (0.024) | 0.013* | 0.019 (0.027) | 0.478 |
| Baseline BCVA (LogMAR) | 0.520 (0.227) | 0.022* | 0.657 (0.300) | 0.028* | 0.250 (0.231) | 0.279 |
| Baseline CST (μm) | −0.002 (0.001) | 0.063 | −0.002 (0.001) | 0.019* | −0.002 (0.001) | 0.002* |
| PDR | 0.005 (0.097) | 0.959 | 0.083 (0.067) | 0.212 | −0.143 (0.061) | 0.019* |
| No of IVI | −0.070 (0.033) | 0.035* | −0.061 (0.032) | 0.053 | −0.017 (0.019) | 0.389 |
B (S.E.): regression coefficient (standard error), BCVA: best corrected visual acuity, CST: central subfield thickness, HbA1C: glycosylated hemoglobin, IVI: intravitreal injection, PDR: Proliferative diabetic retinopathy, *P < 0.05.